Gareth Morgan, MD, PHD, FRCP, FRCPATH

  • Dr-Gareth-Morgan-200x200Dr-Gareth-Morgan-200x200
  • Dr-Gareth-Morgan-200x200Dr-Gareth-Morgan-200x200

G_Doctor_Directoy Category: NYU Langone Medical Center

Related Listing
  • Position: Member of the Faculty, Department of Medicine Director, Multiple Myeloma Research Perlmutter Cancer Center

    Research Focus: Gareth Morgan, M.D. FRCP, FRCPath, Ph.D, Professor of Medicine, is the Director of the Myeloma Institute at UAMS. He is also the deputy director of the Winthrop P. Rockefeller Cancer Institute at UAMS. Dr. Morgan came to UAMS from The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research in London where he was a Professor of Haematology and Director of the Centre for Myeloma Research.

    Dr. Morgan is an internationally recognized clinician scientist who works in the field of molecular genetics of blood cell cancers, in particular, multiple myeloma. He is specifically interested in how this knowledge can improve the treatment of cancer. Dr. Morgan received his doctorate on the genetics of leukemia from the University of London in 1991 and his bachelor of medicine in 1981 from the Welsh National School of Medicine. His post graduate medical training was completed in Wales and at the Royal Postgraduate Medical School in London.

    Dr. Morgan is doing influential work on the characterization of the myeloma genome, defining specific subsets of the disease that have prognostic importance, and developing personalized therapeautic strategies targeted to each subtype. He is also engaged in advanced research in molecular diagnostics, drug development, and clinical trials. His research aims to cure myeloma and to reduce side effects by targeting treatment to the biology underlying each patient’s cancer.

    Before coming to the Myeloma Institute, Dr. Morgan served as a professor of Hematology and director of the Centre for Myeloma Research at the Royal Marsden NHS Foundation Trust and The Institute of Cancer Research in London, Europe’s largest comprehensive cancer institute. He is also a founding director of the European Myeloma Network and has authoried more than 450 peer-reviewed journals.